Martha, one of the park’s oldest gators, gets grabbed in a fight and disappears into deep, murky water. When the team finally spots her, she’s sitting silently on the bottom - wounded and not coming ...

The Bulls N’ Bears ASX Runner of the Week is… Hydrix Ltd, which locked in a $2.5million deal to develop SynCardia’s next-gen ...

Brokers remain positive. The post 3 reasons to buy BlueScope Steel shares now appeared first on The Motley Fool Australia.

With the sun setting on another ‘issues rich’ year for ASX biotechs, Dr Boreham applies his stethoscope to 2025's highlights and lowlights.

Pumping iron isn’t the only way to pump the brakes on age-related muscle loss. While weight training has long been lauded as the key to building and maintaining muscle mass, experts say there are ...

In this piece, we will look at the best ASX stocks to buy. While the Federal Reserve cut interest rates in the US a couple of days back, in Australia, the trend appears to be moving in the opposite ...

Myotonic dystrophy type 1 (DM1) is the most common form of adult-onset muscular dystrophy, affecting about 1 in 8,000 people. While it is well known for causing muscle weakness and stiffness, DM1 also ...

SYDNEY, Dec 3 (Reuters) - The Australian Securities Exchange's technology turnaround plan, touted by the firm's chair as being too important to fail, is facing questions from investors and market ...

George Mycock’s fitness routine had gotten out of hand. The 22-year-old was terrified of putting on body fat but eager to develop more muscle. He tracked his food so thoroughly that he was weighing ...

ASX outage affects 80 stocks, not cybersecurity-related ASX faces criticism from ASIC and RBA over risk management ASX shares down 2.8%, S&P/ASX200 Index down 0.6% Dec 1 (Reuters) - Embattled stock ...

As you age, you gradually lose muscle mass and gain visceral body fat, a type of fat deep inside your body that surrounds your heart, kidneys and other organs. Now, scientists say the ratio of ...

A preliminary review of a phase two clinical trial involving an immunomodulatory therapy drug developed by Antisense Therapeutics (ASX: ANP) has shown a positive effect for patients with non-amubulant ...